학술논문
Steroid-sensitive nephrotic syndrome in children.
Document Type
Article
Source
Subject
*NEPHROTIC syndrome
*SYNDROMES in children
*LEUCOPENIA
*
*
Language
ISSN
0931-0509
Abstract
A group of experts from the International Pediatric Nephrology Association (IPNA) has recently updated recommendations for steroid-resistant and steroid-sensitive nephrotic syndrome (SRNS and SSNS) in children [[1]]. Anti-CD20 monoclonal antibodies (rituximab) [[11]]: indicated in children >7-9 years of age with FRNS or SDNS who are not controlled on therapy after a course of treatment with at least one other steroid-sparing agent at an adequate dose, especially in case of non-adherence. Sequential rituximab therapy sustains remission of nephrotic syndrome but carries high risk of adverse effects. [Extracted from the article]